Patents by Inventor Helmut Macke

Helmut Macke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140023585
    Abstract: The invention is directed to novel Lutetium-177-labeled bombesin analogs for treatment of tumor by radiotherapy.
    Type: Application
    Filed: November 21, 2011
    Publication date: January 23, 2014
    Applicants: UNIVERSITATSSPITAL BASEL, PIRAMAL IMAGING SA
    Inventors: Sandra Borkowski, Rosalba Mansi, Helmut Macke
  • Publication number: 20070053837
    Abstract: Radionuclide labelled conjugates based on substance P and analogues thereof with the chelator (DOTAGA) (1-(1-rarboxy-3-carboxy-propyl)-4,7,10(carboxymethyl)-1,4,7,10-tetraazacyclo-dodecane, DOTASA (1-(1-carboxy-2carboxy-ethyl)-4,7,10(carboxymethyl)1,4,7,10-tetraazacyclo-dodecane, or chelator (DOTA) [1,4,7,10 tetraazaacyclo-dodecane 1,4,7,10-tetra(acetic acid)] are useful radiopharmaceutical substances for targeting and treatment of brain tumors, especially gliomas.
    Type: Application
    Filed: March 18, 2004
    Publication date: March 8, 2007
    Applicants: Kantonsspital Basel, Universitat Bern
    Inventors: Adrian Merlo, Helmut Macke, Jean-Claude Reubi, Stephan Good
  • Patent number: 5650134
    Abstract: Somatostatin peptides bearing a chelating group selected from a bifunctional N.sub.4 -chelating group particularly suitable for Tc, Rh, Cu, Co or Re-labelling, and a bifunctional polyamino-polycarboxylic acid chelating group are complexed with a .alpha.-, .beta.-, .gamma.- or positron-emitting nuclide or a nuclide with Auger-e.sup.- -cascades and are useful as radiopharmaceuticals.
    Type: Grant
    Filed: July 12, 1995
    Date of Patent: July 22, 1997
    Assignee: Novartis AG (formerly Sandoz Ltd.)
    Inventors: Rainer Albert, Helmut Macke